Sleep disorders in patients with severe mental depression: Double-blind placebo-controlled evaluation of the value of pipamperone (Dipiperon®)

Abstract

Pipamperone was compared double-blindly with placebo to evaluate its capacity to relieve sleep disorders in 40 depressive inpatients. At the end of the 1 wk trial, most of the items relating to sleep disturbances had improved significantly in the 24 patients of the pipamperone group, whereas only a few items showed such a change in the control group. On the Hamilton depression scale, improvmeent in the pipamperone patients was also superior to that in the placebo group as regards the items depressed mood and insight. The adequate median daily dose of pipamperone appeared to be 80 mg (2 tablets).